Bryan Head

BCG Roundtable Focused on Key Trends Shaping the Future of Clinical Operations   Was thrilled to host an energetic discussion at our inaugural Clinical Operations roundtable earlier this week with industry executives across biopharma to discuss the most pressing topics shaping these teams. Thank you to our BCG team that enabled this discussion John Wu, Najaf A. Shah Shah, Paul Hastwell, Deming Qin Rachel Magid Beatriz Monedero Álvarez. Four Key Trends from the Roundtable: 1. Simplifying Protocols to Improve Patient-Centricity and Equity Growing emphasis on reducing patient burden during clinical trials is reshaping clinical operations and clinical trial decision-making more broadly. Companies are leveraging data and analytics to design smarter, more inclusive trials while simplifying protocols for patients and sites. They are also bringing in patients to shape their protocols 2. Continuing to Accelerate Trial Timelines Site Activation and patient enrolment remain critical bottlenecks and a key discussion point, with participants sharing the strategies and initiatives they are pursuing (e.g., trial footprint and site mix adjustments, digital recruitment approaches and evolving site facing roles) to deliver trials faster. 3. Evolving Sourcing Models: To boost efficiency and capacity, companies are rethinking resource allocation, exploring more offshoring and functional service provider (FSP) to manage capacity; Full-service outsourcing (FSO) models still have a role, particularly for mid-sized companies and select studies 4. Harnessing (Gen)AI: GenAI is revolutionizing trial operations, from AI-powered design tools, automated document generation and dashboards to decentralized research and patient engagement. These innovations are set to enhance trial delivery and patient experience. Exciting times for Clinical Operations teams as they play a critical role in bringing medicines to patients faster in a cost-effective and efficient manner, with greater consideration of the patient experience and needs. To join us in future discussions, please get in touch at [email protected] #clinical, #trials, #GenAI

79

5 Comments

FTI Consulting's Jason Shafrin,PhD, and Jaehong Kim, PhD, have published an innovative study that reimagines how we evaluate healthcare technologies and treatments. Our new Generalized Cost-Effectiveness Analysis (GCEA) framework goes beyond traditional metrics to consider 15 key value elements that matter to society, including: -How treatments affect patient confidence and risk -Long-term benefits as treatments evolve -Impact on caregivers and communities -Broader societal benefits like workplace productivity Why this matters: Current methods often miss important benefits of new healthcare technologies. Our user guide makes it easier to capture these broader impacts, leading to better-informed healthcare decisions. Read our complete framework and user guide below. #Healthcare #HealthEconomics #ValueBasedCare #FTIConsulting #Research #HealthcareInnovation

2

Amid tightening budgets, 50% of the top 20 leading pharma firms are prioritizing technology to achieve efficiency gains, as pressures on clinical services spending continue to grow. Uncover strategies for life sciences service providers to drive performance in a challenging market environment. https://atbain.co/41dK839

2

Amid tightening budgets, 50% of the top 20 leading pharma firms are prioritizing technology to achieve efficiency gains, as pressures on clinical services spending continue to grow. Uncover strategies for life sciences service providers to drive performance in a challenging market environment. https://atbain.co/3V0Ve7X

4

Are you navigating the complexities of managing costs while fueling growth?​ ​ As costs continue to pressure margins, many organizations focus on quick wins in cost reduction, but sustaining these gains requires more than just short-term fixes. New BCG research underscores the importance of reinvesting savings into strategic innovations that drive future growth. Leaders who master this balance are better positioned to thrive in the evolving energy landscape.​ ​ Read how a strategic approach to cost management can unlock growth opportunities here – https://lnkd.in/dnU7Rkfv

76

My colleagues, Eric Berger, Robbie Sandig, and KC George shares how large and small pharma companies are succeeding with generative AI and the three-tiered approach guiding them to the forefront. Key takeaways include the importance of priming operating models and leveraging scale for breakthroughs.

3

1 Comment

Axios highlighted Bain analysis showing companies further accelerating reshoring and near-shoring amid heightened geopolitical uncertainties and rising costs. Hernan Saenz, head of Bain’s Performance Improvement practice, discussed the trend with Axios chief economics correspondent Neil Irwin.

1

Amid tightening budgets, 50% of the top 20 leading pharma firms are prioritizing technology to achieve efficiency gains, as pressures on clinical services spending continue to grow. Uncover strategies for life sciences service providers to drive performance in a challenging market environment. https://atbain.co/3AHy5k1

2

FTI Consulting's Jason Shafrin, was recently featured in The Evidence Base® discussing the newly published paper, “Valuing the Societal Impact of Medicines and Other Health Technologies.” This user guide introduces generalized cost-effectiveness analysis (GCEA), a groundbreaking framework designed to provide a more inclusive approach to drug valuation and health policy decision-making. In this interview, Jason uncovers: • Why GCEA is a game-changer for healthcare decision-making • How GCEA addresses the limitations of traditional cost-effectiveness analysis (CEA) • The potential impact on healthcare policy and access to medicines Read the full interview below. *This article requires a log in, free account can be created to access the full article #Healthcare #HealthcareAccess #HealthcareInnovation #DrugValuation #FTIConsulting

2

Check out my BCG colleagues recent report that focuses on improving #healthequity with patient analytics. The research unveils significant disparities in the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF) across the United States. Focusing on areas with notably low engagement, particularly in under-served urban areas. Explore the findings and actionable strategies here: https://lnkd.in/ec-GHthB

7

Axios highlighted Bain analysis showing companies further accelerating reshoring and near-shoring amid heightened geopolitical uncertainties and rising costs. Hernan Saenz, head of Bain’s Performance Improvement practice, discussed the trend with Axios chief economics correspondent Neil Irwin.

2

Excited to share Alvarez & Marsal's latest Private Equity Value Creation Survey, where Markus Lahrkamp and Rachel Jurgensmeyer offer a deep dive into the strategies driving portfolio growth today. From digital transformation to operational efficiency, we're seeing new trends emerge that are reshaping how value is built and sustained. This survey is a must-read for those aiming to stay ahead in an evolving landscape. Explore the full insights here: https://lnkd.in/gZRJMQJM #PrivateEquity #PerformanceImprovement #ValueCreation #Strategy

37

The past two years have been challenging for investors in the healthcare provider sector– but underlying trends that make provider investments attractive persist. Focusing on four capabilities—patient engagement, care delivery, productivity solutions, and new opportunities—could help spur performance and ensure long-term viability. Learn more in our latest McKinsey Healthcare Blog. ⬇️

25

BCG and Merck – or MSD, as it is known outside of the U.S. and Canada – are embarking on an exciting new collaboration centered on using GenAI to discover new drug formulas while assessing novel targets to help better treat chronic and degenerative diseases.   I am interested to see how advanced technologies like these will continue to make way for more innovative solutions to some of the toughest medical challenges of our time. Don’t just take my word for it. Check out this fascinating dialogue between Sylvain Duranton, Global Leader of BCG X, and Iya Khalil, Head of Data, AI, and Genome Sciences at Merck to learn more.   #HealthcareInnovation #GenerativeAI

8

1 Comment

Indeed - Supply Chain Planning Solutions and the challenges to get it right is top of mind of many life science operations leadership teams … Hence the exchange of learnings amongst experts is super valuable

1